Apoptosis in cancer: from pathogenesis to discovery of advanced selective Bcl-2 family inhibitors

Archives of Pharmaceutical Sciences Ain Shams University

Nermin S. Abdou¹  Deena S. Lasheen¹  Dalal A. Abou El Ella²  Samaa Abbas³ 

[1] Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt;Pharmaceutical Chemistry Department, Faculty of Pharmacy, El-Nahda University, Beni sweif, Egypt;Pharmaceutical Chemistry, Faculty of Pharmacy, ASU, Cairo, Egypt;

关键词: apoptosis;    Bcl-2;    Extrinsic pathway;    Intrinsic pathway;    Caspase;    BH3;   

DOI  :  https://dx.doi.org/10.21608/aps.2019.20225

来源: DOAJ

【 摘 要 】

Cancer is a genetic disease characterized by two features: unregulated cell growth and tissue invasion (metastasis). It can be viewed as the result of a succession of genetic changes during which a normal cell is transformed into a malignant one. Evasion of cell death, apoptosis, is one of the essential changes in a cell that cause this malignant transformation. Hence, reduced apoptosis or its resistance plays a vital role in carcinogenesis. The Bcl-2 family of proteins regulates the mitochondrial apoptotic pathway. Disease states arise upon deregulation of the Bcl-2 family of proteins, where cell death is either promoted or evaded; one of the most common tactic cancer cells utilize to promote survival is anti-apoptotic protein overexpression. Specifically, Bcl-2 overexpression has been shown to be a major chemoresistance factor in a number of human cancers, and for this reason, Bcl-2 targeting is a pharmacologic priority in the quest to reactivate cell death for therapeutic benefit in cancer.

【 授权许可】

Unknown